{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T08:45:24Z","timestamp":1762677924443,"version":"build-2065373602"},"reference-count":26,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We describe the case of a patient in his 70s with Parkinson disease (PD) who had an incidental pheochromocytoma with mesenteric secondaries. Although the literature contains a few case reports of patients with PD who have incidental pheochromocytoma, this is the first case report of a patient with PD and metastatic paraganglioma (PPGL). The diagnosis was confirmed by a metaiodobenzylguanidine radioisotopic scan, along with increased levels of catecholaminergic products and byproducts in the urine. Genetic predisposition to PD and PPGL appears paradoxical, as PPGL is associated with the pathologic stabilization of hypoxia-inducible factor-1\u03b1. In contrast, PD involves the disruption of hypoxia-inducible factor-1\u03b1 activity. Thus, the coexistence of these 2 conditions should be very rare, and, based on the paucity of such cases in the literature, this appears to be the case.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf262","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T08:42:43Z","timestamp":1762677763000},"source":"Crossref","is-referenced-by-count":0,"title":["A Unique Case of Metastatic Paraganglioma in a Patient With Parkinson Disease"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1854-7458","authenticated-orcid":false,"given":"Soe Theingi","family":"Aye","sequence":"first","affiliation":[{"name":"Elderly Care Medicine Department, Salisbury NHS Foundation Trust, Salisbury SP2 8BJ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5549-6398","authenticated-orcid":false,"given":"Theik Di","family":"Oo","sequence":"additional","affiliation":[{"name":"Elderly Care Medicine Department, Salisbury NHS Foundation Trust, Salisbury SP2 8BJ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9579-485X","authenticated-orcid":false,"given":"Nyein Aye","family":"Lwin","sequence":"additional","affiliation":[{"name":"Elderly Care Medicine Department, Salisbury NHS Foundation Trust, Salisbury SP2 8BJ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"2","key":"2025110903423945200_luaf262-B1","first-page":"159","article-title":"Pheochromocytoma and paraganglioma: from epidemiology to clinical findings.","volume":"54","author":"Aygun","year":"2020","journal-title":"Sisli Etfal Hastan Tip Bul"},{"issue":"1","key":"2025110903423945200_luaf262-B2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.currproblcancer.2014.01.001","article-title":"Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.","volume":"38","author":"Martucci","year":"2014","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"2025110903423945200_luaf262-B3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev"},{"issue":"5","key":"2025110903423945200_luaf262-B4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3390\/cancers11050683","article-title":"Pheochromocytomas and paragangliomas: bypassing cellular respiration","volume":"11","author":"Casc\u00f3n","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"19","key":"2025110903423945200_luaf262-B5","doi-asserted-by":"crossref","first-page":"10484","DOI":"10.3390\/ijms251910484","article-title":"Hypoxia pathways in Parkinson's disease: from pathogenesis to therapeutic targets","volume":"25","author":"Gao","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2025110903423945200_luaf262-B6","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2169\/internalmedicine.9242-17","article-title":"A rare coexistence of pheochromocytoma and Parkinson's disease with diagnostic challenges","volume":"57","author":"Matsumura-Matsuda","year":"2018","journal-title":"Internal Medicine"},{"issue":"6","key":"2025110903423945200_luaf262-B7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrneurol.2009.55","article-title":"Diagnosis of pheochromocytoma in the setting of Parkinson disease","volume":"5","author":"Mehta","year":"2009","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"2025110903423945200_luaf262-B8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2265.2011.04266.x","article-title":"A phaeochromocytoma occurring in a patient with Parkinson's disease on L-Dopa therapy: a diagnostic challenge","volume":"76","author":"Collier","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2025110903423945200_luaf262-B9","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.4158\/EP13511.CR","article-title":"Diagnostic challenge of pheochromocytoma in a patient receiving levodopa for Parkinson's disease","volume":"20","author":"Shimodaira","year":"2014","journal-title":"Endocr Pract"},{"issue":"42","key":"2025110903423945200_luaf262-B10","doi-asserted-by":"crossref","first-page":"e1855","DOI":"10.1097\/MD.0000000000001855","article-title":"Adrenal pheochromocytoma incidentally discovered in a patient with Parkinsonism","volume":"94","author":"Petramala","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2025110903423945200_luaf262-B11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/CRD.0b013e3181a6de40","article-title":"Paragangliomas: etiology, presentation, and management.","volume":"17","author":"Joynt","year":"2009","journal-title":"Cardiol Rev"},{"issue":"1","key":"2025110903423945200_luaf262-B12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1196\/annals.1353.002","article-title":"Paragangliomas: clinical overview","volume":"1073","author":"Young","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"2025110903423945200_luaf262-B13","volume-title":"Pheochromocytoma and Paraganglioma Treatment (PDQ\u00ae)\u2013Patient Version","author":"National Cancer Institute","year":"2024"},{"issue":"2","key":"2025110903423945200_luaf262-B14","doi-asserted-by":"crossref","first-page":"e241147","DOI":"10.1136\/bcr-2020-241147","article-title":"False elevations in urinary metanephrines: under-recognised pitfall with 24-hour urinary volume collection.","volume":"14","author":"Shin","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"4","key":"2025110903423945200_luaf262-B15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2017.5926","article-title":"Metanephrines for evaluating palpitations and flushing.","volume":"318","author":"Hannah-Shmouni","year":"2017","journal-title":"JAMA"},{"issue":"Pt 1","key":"2025110903423945200_luaf262-B16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0004563213487894","article-title":"Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine","volume":"51","author":"Eisenhofer","year":"2014","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"2025110903423945200_luaf262-B17","first-page":"3151","article-title":"Current diagnostic imaging of pheochromocytomas and implications for therapeutic strategy (review)","volume":"15","author":"\u010ctvrtl\u00edk","year":"2018","journal-title":"Exp Ther Med"},{"issue":"6","key":"2025110903423945200_luaf262-B18","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025110903423945200_luaf262-B19","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1210\/clinem\/dgz074","article-title":"Long-Term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131-I MIBG.","volume":"105","author":"Thorpe","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025110903423945200_luaf262-B20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neurol.2015.09.012","article-title":"Epidemiology of Parkinson's disease","volume":"172","author":"Elbaz","year":"2016","journal-title":"Rev Neurol (Paris)"},{"key":"2025110903423945200_luaf262-B21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.arr.2014.01.004","article-title":"Ageing and Parkinson's disease: why is advancing age the biggest risk factor?","volume":"14","author":"Reeve","year":"2014","journal-title":"Ageing Res Rev"},{"issue":"6","key":"2025110903423945200_luaf262-B22","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.3390\/ijms10062510","article-title":"Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders","volume":"10","author":"Choonara","year":"2009","journal-title":"Int J Mol Sci"},{"issue":"s1","key":"2025110903423945200_luaf262-B23","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3233\/JPD-181493","article-title":"The search for environmental causes of Parkinson's disease: moving forward","volume":"8","author":"Chen","year":"2018","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2025110903423945200_luaf262-B24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s43055-021-00454-9","article-title":"Imaging modalities in differential diagnosis of Parkinson's disease: opportunities and challenges","volume":"52","author":"Mortezazadeh","year":"2021","journal-title":"Egypt J Radiol Nucl Med"},{"key":"2025110903423945200_luaf262-B25"},{"issue":"9","key":"2025110903423945200_luaf262-B26","doi-asserted-by":"crossref","first-page":"bvac105","DOI":"10.1210\/jendso\/bvac105","article-title":"Systematic review: incidence of pheochromocytoma and paraganglioma over 70 years","volume":"6","author":"Al Subhi","year":"2022","journal-title":"J Endocr Soc"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/12\/luaf262\/65240049\/luaf262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/12\/luaf262\/65240049\/luaf262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T08:42:45Z","timestamp":1762677765000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf262\/8316647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf262","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,27]]},"article-number":"luaf262"}}